Data compiled by Redley Lamar · ChainSifter Intelligence
6Suppliers
2Customers
1Debt Items
20Related Chains
Source-Backed Evidence Depth
Purple Biotech Ltd (PPBT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
10Total relationships
2Distinct source URLs
4High confidence
0.796Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Purple Biotech Ltd Suppliers
Ticker
Name
Confidence
Evidence
BMY
Bristol-Myers Squibb Company
92%
We entered into a clinical collaboration and supply agreement with Bristol Myers Squibb Company (NYSE:BMY) for the phase 1/2 study of CM24 in combination with a programmed cell death protein 1 (PD-1)…
BMY
Bristol-Myers Squibb Company
92%
Reciprocal relationship from BMY graph: Reciprocal relationship from PPBT graph: Reciprocal relationship from BMY graph: Reciprocal relationship from PPBT graph: We entered into a clinical collaborat…
Reciprocal relationship from BTTC graph: Reciprocal relationship from PPBT graph: Reciprocal relationship from BTTC graph: Reciprocal relationship from PPBT graph: Reciprocal relationship from BTTC g…
letion of these trials and adversely affect our ability to advance the development of our therapeutic candidates. Even if we can enroll a sufficient number of patients in our clinical trials, delays …
Reciprocal relationship from CELG-RI graph: Reciprocal relationship from PPBT graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from PPBT graph: Reciprocal relationship from …
Reciprocal relationship from KMDA graph: they will be utilized. Deductible carryforward losses and temporary differences for which deferred tax assets have not been recognized are reviewed at the end…
letion of these trials and adversely affect our ability to advance the development of our therapeutic candidates. Even if we can enroll a sufficient number of patients in our clinical trials, delays …
Reciprocal relationship from CELG-RI graph: Reciprocal relationship from PPBT graph: letion of these trials and adversely affect our ability to advance the development of our therapeutic candidates. …
Purple Biotech Ltd Debt Obligations
Instrument
Description
Confidence
Evidence
PPBT-DEBT
Debt stack $184,000
90%
Market cache reports total debt of $184,000.
Purple Biotech Ltd Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Purple Biotech Ltd.
Purple Biotech Ltd Ownership
Holder
Name
Confidence
Evidence
PPBT-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 2 tracked holders.
